| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 166 | 2022 | 3976 | 9.490 |
Why?
|
| Carcinoma, Squamous Cell | 130 | 2022 | 5437 | 4.950 |
Why?
|
| Salivary Gland Neoplasms | 49 | 2021 | 489 | 4.900 |
Why?
|
| Laryngeal Neoplasms | 38 | 2019 | 518 | 3.320 |
Why?
|
| Carcinoma, Adenoid Cystic | 34 | 2019 | 421 | 3.260 |
Why?
|
| Neck Dissection | 29 | 2022 | 290 | 2.330 |
Why?
|
| Laryngectomy | 24 | 2020 | 242 | 2.240 |
Why?
|
| Tongue Neoplasms | 12 | 2018 | 246 | 2.120 |
Why?
|
| Oropharyngeal Neoplasms | 29 | 2019 | 1105 | 2.040 |
Why?
|
| Thyroid Neoplasms | 28 | 2019 | 1866 | 1.950 |
Why?
|
| Carcinoma, Mucoepidermoid | 11 | 2017 | 137 | 1.880 |
Why?
|
| Quality Indicators, Health Care | 7 | 2018 | 348 | 1.830 |
Why?
|
| Skin Neoplasms | 27 | 2021 | 4654 | 1.490 |
Why?
|
| Neoplasm Staging | 69 | 2022 | 13658 | 1.380 |
Why?
|
| Quality Improvement | 7 | 2020 | 851 | 1.350 |
Why?
|
| Neoplasm Recurrence, Local | 57 | 2022 | 10035 | 1.290 |
Why?
|
| Surgical Procedures, Operative | 7 | 2011 | 383 | 1.270 |
Why?
|
| Periodicals as Topic | 19 | 2011 | 338 | 1.260 |
Why?
|
| Carcinoma | 23 | 2020 | 2578 | 1.230 |
Why?
|
| Quality Assurance, Health Care | 8 | 2015 | 585 | 1.200 |
Why?
|
| Humans | 393 | 2023 | 261506 | 1.200 |
Why?
|
| Middle Aged | 222 | 2021 | 86204 | 1.170 |
Why?
|
| Patient Care Team | 7 | 2020 | 795 | 1.150 |
Why?
|
| Lymphatic Metastasis | 37 | 2021 | 4844 | 1.150 |
Why?
|
| Aged | 197 | 2022 | 70117 | 1.140 |
Why?
|
| Carcinoma, Basal Cell | 10 | 2019 | 272 | 1.130 |
Why?
|
| Submandibular Gland Neoplasms | 6 | 2016 | 37 | 1.110 |
Why?
|
| Parotid Neoplasms | 11 | 2017 | 148 | 1.080 |
Why?
|
| Male | 250 | 2021 | 123000 | 1.070 |
Why?
|
| Aged, 80 and over | 119 | 2021 | 29902 | 1.050 |
Why?
|
| Guideline Adherence | 5 | 2019 | 636 | 1.040 |
Why?
|
| Cancer Care Facilities | 8 | 2022 | 884 | 1.010 |
Why?
|
| Adult | 183 | 2021 | 77950 | 1.000 |
Why?
|
| Xerostomia | 9 | 2014 | 190 | 0.960 |
Why?
|
| Female | 233 | 2021 | 141928 | 0.940 |
Why?
|
| Retrospective Studies | 106 | 2022 | 37905 | 0.920 |
Why?
|
| Combined Modality Therapy | 66 | 2017 | 8865 | 0.900 |
Why?
|
| Academic Medical Centers | 6 | 2016 | 672 | 0.880 |
Why?
|
| Cisplatin | 16 | 2022 | 2432 | 0.870 |
Why?
|
| Otolaryngology | 15 | 2008 | 129 | 0.840 |
Why?
|
| Paranasal Sinus Neoplasms | 10 | 2023 | 285 | 0.840 |
Why?
|
| Neck | 14 | 2015 | 383 | 0.810 |
Why?
|
| Publishing | 14 | 2008 | 220 | 0.810 |
Why?
|
| Radiotherapy, Intensity-Modulated | 14 | 2019 | 2104 | 0.790 |
Why?
|
| Surgical Oncology | 2 | 2020 | 190 | 0.770 |
Why?
|
| Editorial Policies | 15 | 2007 | 87 | 0.770 |
Why?
|
| Prognosis | 69 | 2021 | 21713 | 0.770 |
Why?
|
| Organization and Administration | 1 | 2020 | 8 | 0.760 |
Why?
|
| Pharyngeal Neoplasms | 10 | 2016 | 133 | 0.760 |
Why?
|
| Civil Defense | 1 | 2020 | 13 | 0.750 |
Why?
|
| Interdisciplinary Communication | 4 | 2020 | 280 | 0.740 |
Why?
|
| Radiotherapy, Adjuvant | 21 | 2020 | 2231 | 0.740 |
Why?
|
| Postoperative Complications | 25 | 2022 | 5542 | 0.730 |
Why?
|
| Chemoradiotherapy | 14 | 2022 | 1946 | 0.730 |
Why?
|
| Survival Rate | 50 | 2022 | 12221 | 0.720 |
Why?
|
| Surgical Flaps | 15 | 2020 | 927 | 0.710 |
Why?
|
| Practice Guidelines as Topic | 9 | 2020 | 2403 | 0.700 |
Why?
|
| Body Image | 2 | 2011 | 141 | 0.690 |
Why?
|
| Carcinoma, Papillary | 7 | 2017 | 584 | 0.670 |
Why?
|
| Submandibular Gland | 3 | 2016 | 20 | 0.670 |
Why?
|
| Critical Pathways | 5 | 2020 | 149 | 0.670 |
Why?
|
| Disease-Free Survival | 38 | 2021 | 10001 | 0.650 |
Why?
|
| Nasopharyngeal Neoplasms | 9 | 2016 | 323 | 0.640 |
Why?
|
| Nose Neoplasms | 10 | 2019 | 229 | 0.640 |
Why?
|
| Salvage Therapy | 13 | 2022 | 2054 | 0.630 |
Why?
|
| Mouth Neoplasms | 14 | 2022 | 713 | 0.630 |
Why?
|
| Neoplasm Invasiveness | 28 | 2020 | 3981 | 0.630 |
Why?
|
| Specialties, Surgical | 2 | 2019 | 137 | 0.620 |
Why?
|
| Surgical Wound Infection | 11 | 2020 | 450 | 0.610 |
Why?
|
| Thyroidectomy | 6 | 2014 | 486 | 0.610 |
Why?
|
| Translocation, Genetic | 4 | 2016 | 1245 | 0.580 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 164 | 0.560 |
Why?
|
| Lymph Node Excision | 12 | 2008 | 1959 | 0.560 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2016 | 60 | 0.560 |
Why?
|
| Medical Oncology | 5 | 2020 | 1423 | 0.550 |
Why?
|
| Survival Analysis | 31 | 2020 | 9180 | 0.550 |
Why?
|
| Transcriptome | 6 | 2023 | 1859 | 0.550 |
Why?
|
| Radiotherapy | 15 | 2017 | 1824 | 0.550 |
Why?
|
| Adolescent | 58 | 2019 | 31252 | 0.540 |
Why?
|
| Lymph Nodes | 13 | 2020 | 2967 | 0.530 |
Why?
|
| Salivary Ducts | 6 | 2021 | 56 | 0.530 |
Why?
|
| Follow-Up Studies | 44 | 2020 | 14889 | 0.530 |
Why?
|
| Tonsillar Neoplasms | 2 | 2014 | 80 | 0.530 |
Why?
|
| Intraoperative Complications | 4 | 2020 | 301 | 0.520 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.520 |
Why?
|
| Fees, Medical | 1 | 2014 | 11 | 0.520 |
Why?
|
| Feedback, Psychological | 1 | 2015 | 18 | 0.520 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.520 |
Why?
|
| Deglutition | 7 | 2017 | 171 | 0.510 |
Why?
|
| Treatment Outcome | 65 | 2022 | 32848 | 0.510 |
Why?
|
| Young Adult | 30 | 2020 | 21445 | 0.500 |
Why?
|
| Length of Stay | 10 | 2022 | 1900 | 0.500 |
Why?
|
| Skin Transplantation | 4 | 2000 | 173 | 0.490 |
Why?
|
| Oncogene Proteins, Fusion | 6 | 2019 | 755 | 0.490 |
Why?
|
| Medical Audit | 1 | 2015 | 188 | 0.480 |
Why?
|
| Facial Nerve | 2 | 2011 | 64 | 0.470 |
Why?
|
| Carcinoma, Ductal | 4 | 2021 | 145 | 0.460 |
Why?
|
| Patient Readmission | 6 | 2019 | 548 | 0.460 |
Why?
|
| Quality of Life | 14 | 2018 | 4532 | 0.450 |
Why?
|
| Hypopharyngeal Neoplasms | 9 | 2017 | 82 | 0.450 |
Why?
|
| Blood Transfusion | 3 | 2007 | 583 | 0.440 |
Why?
|
| Jugular Veins | 2 | 2004 | 107 | 0.430 |
Why?
|
| Thyroid Gland | 5 | 2019 | 355 | 0.430 |
Why?
|
| DNA, Neoplasm | 6 | 2016 | 1910 | 0.430 |
Why?
|
| Risk Assessment | 15 | 2019 | 6869 | 0.420 |
Why?
|
| Neurilemmoma | 2 | 2006 | 127 | 0.420 |
Why?
|
| Microsurgery | 7 | 2012 | 244 | 0.420 |
Why?
|
| Laser Therapy | 2 | 2007 | 411 | 0.420 |
Why?
|
| Parathyroid Glands | 2 | 2008 | 127 | 0.420 |
Why?
|
| Adenocarcinoma | 14 | 2023 | 7789 | 0.420 |
Why?
|
| Radiopharmaceuticals | 7 | 2017 | 1301 | 0.410 |
Why?
|
| Temporal Bone | 3 | 2011 | 102 | 0.410 |
Why?
|
| Mandible | 3 | 2022 | 188 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2019 | 15862 | 0.400 |
Why?
|
| Benchmarking | 2 | 2019 | 273 | 0.390 |
Why?
|
| Nomograms | 3 | 2018 | 313 | 0.390 |
Why?
|
| Radiotherapy Dosage | 27 | 2017 | 3842 | 0.390 |
Why?
|
| Trans-Activators | 8 | 2016 | 1555 | 0.380 |
Why?
|
| Program Evaluation | 3 | 2020 | 597 | 0.380 |
Why?
|
| Carboplatin | 3 | 2011 | 823 | 0.380 |
Why?
|
| Laryngoscopy | 9 | 2014 | 183 | 0.370 |
Why?
|
| Health Policy | 1 | 2013 | 291 | 0.370 |
Why?
|
| Facial Paralysis | 1 | 2010 | 60 | 0.370 |
Why?
|
| Quinuclidines | 2 | 2007 | 48 | 0.370 |
Why?
|
| Radiation-Protective Agents | 3 | 2007 | 128 | 0.360 |
Why?
|
| Hypopharynx | 3 | 2012 | 21 | 0.360 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 671 | 0.360 |
Why?
|
| Neoadjuvant Therapy | 8 | 2021 | 4975 | 0.360 |
Why?
|
| Orbit Evisceration | 1 | 2010 | 46 | 0.360 |
Why?
|
| Face | 2 | 2010 | 273 | 0.360 |
Why?
|
| Transcription Factors | 9 | 2016 | 5270 | 0.360 |
Why?
|
| Biomarkers, Tumor | 26 | 2023 | 10331 | 0.350 |
Why?
|
| Parathyroid Neoplasms | 3 | 2006 | 185 | 0.350 |
Why?
|
| Deglutition Disorders | 8 | 2017 | 447 | 0.350 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 3343 | 0.350 |
Why?
|
| Thiophenes | 2 | 2007 | 148 | 0.350 |
Why?
|
| Neoplasms, Multiple Primary | 5 | 2010 | 551 | 0.340 |
Why?
|
| Robotics | 4 | 2012 | 359 | 0.340 |
Why?
|
| Parathyroid Diseases | 1 | 2008 | 17 | 0.330 |
Why?
|
| Parotid Gland | 5 | 2012 | 112 | 0.330 |
Why?
|
| Risk Factors | 33 | 2022 | 17523 | 0.330 |
Why?
|
| Logistic Models | 6 | 2020 | 3441 | 0.330 |
Why?
|
| Operating Rooms | 2 | 2019 | 122 | 0.320 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2008 | 69 | 0.320 |
Why?
|
| DNA-Binding Proteins | 5 | 2016 | 4821 | 0.320 |
Why?
|
| Angiofibroma | 3 | 2003 | 17 | 0.310 |
Why?
|
| Phosphoproteins | 3 | 2011 | 1152 | 0.310 |
Why?
|
| Self Efficacy | 1 | 2010 | 298 | 0.310 |
Why?
|
| Positron-Emission Tomography | 5 | 2010 | 2173 | 0.310 |
Why?
|
| Head | 4 | 2005 | 249 | 0.310 |
Why?
|
| Cervical Vertebrae | 4 | 2005 | 205 | 0.310 |
Why?
|
| Surgeons | 1 | 2015 | 519 | 0.310 |
Why?
|
| Interpersonal Relations | 1 | 2010 | 290 | 0.310 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2008 | 132 | 0.310 |
Why?
|
| Immunohistochemistry | 17 | 2019 | 7548 | 0.300 |
Why?
|
| Quinazolines | 2 | 2012 | 923 | 0.300 |
Why?
|
| Amifostine | 2 | 2004 | 97 | 0.300 |
Why?
|
| Eye Neoplasms | 1 | 2010 | 247 | 0.300 |
Why?
|
| Larynx | 7 | 2017 | 134 | 0.300 |
Why?
|
| Cohort Studies | 18 | 2018 | 9244 | 0.290 |
Why?
|
| Gingival Neoplasms | 2 | 1996 | 6 | 0.290 |
Why?
|
| Cervicoplasty | 1 | 2006 | 6 | 0.290 |
Why?
|
| Blood Loss, Surgical | 2 | 2007 | 309 | 0.290 |
Why?
|
| Oropharynx | 2 | 2010 | 74 | 0.290 |
Why?
|
| Parathyroidectomy | 1 | 2008 | 203 | 0.290 |
Why?
|
| Oxyphil Cells | 1 | 2006 | 7 | 0.290 |
Why?
|
| Granular Cell Tumor | 1 | 2006 | 22 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2019 | 6207 | 0.290 |
Why?
|
| United States | 20 | 2020 | 15433 | 0.290 |
Why?
|
| Pharynx | 6 | 2016 | 153 | 0.290 |
Why?
|
| Teratoma | 2 | 2019 | 236 | 0.290 |
Why?
|
| Muscarinic Antagonists | 1 | 2007 | 83 | 0.280 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2020 | 3890 | 0.280 |
Why?
|
| Cluster Analysis | 5 | 2019 | 1053 | 0.280 |
Why?
|
| Societies, Medical | 3 | 2011 | 1335 | 0.280 |
Why?
|
| Population Surveillance | 3 | 2019 | 627 | 0.280 |
Why?
|
| Graft Survival | 2 | 2000 | 1062 | 0.280 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2010 | 1226 | 0.280 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2006 | 121 | 0.280 |
Why?
|
| Proportional Hazards Models | 10 | 2021 | 4988 | 0.280 |
Why?
|
| Organ Sparing Treatments | 4 | 2019 | 277 | 0.280 |
Why?
|
| Recovery of Function | 5 | 2020 | 703 | 0.270 |
Why?
|
| Salivary Glands | 7 | 2019 | 130 | 0.270 |
Why?
|
| Neoplasm, Residual | 6 | 2018 | 1656 | 0.270 |
Why?
|
| Fiber Optic Technology | 1 | 2006 | 142 | 0.270 |
Why?
|
| Reoperation | 8 | 2020 | 1382 | 0.270 |
Why?
|
| ErbB Receptors | 8 | 2012 | 2295 | 0.260 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 764 | 0.260 |
Why?
|
| Clindamycin | 3 | 1993 | 50 | 0.260 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2019 | 2232 | 0.260 |
Why?
|
| Gastrostomy | 6 | 2020 | 180 | 0.260 |
Why?
|
| Skull | 4 | 2002 | 231 | 0.250 |
Why?
|
| NFI Transcription Factors | 3 | 2015 | 74 | 0.250 |
Why?
|
| Free Tissue Flaps | 2 | 2019 | 372 | 0.250 |
Why?
|
| Carcinoma, Medullary | 2 | 2004 | 248 | 0.250 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2004 | 28 | 0.250 |
Why?
|
| Multivariate Analysis | 10 | 2020 | 4298 | 0.250 |
Why?
|
| Child | 27 | 2021 | 29154 | 0.240 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 2 | 2015 | 110 | 0.240 |
Why?
|
| Clinical Competence | 2 | 2011 | 1270 | 0.240 |
Why?
|
| Patient Care Planning | 3 | 2018 | 297 | 0.240 |
Why?
|
| Papillomavirus Infections | 6 | 2019 | 980 | 0.240 |
Why?
|
| Iodine Radioisotopes | 2 | 2017 | 371 | 0.240 |
Why?
|
| Cerebrovascular Disorders | 2 | 2008 | 142 | 0.230 |
Why?
|
| Antineoplastic Agents | 11 | 2016 | 14289 | 0.230 |
Why?
|
| Time Factors | 20 | 2020 | 12926 | 0.230 |
Why?
|
| Proteomics | 1 | 2011 | 1380 | 0.230 |
Why?
|
| Gene Expression Profiling | 8 | 2019 | 5159 | 0.230 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 2576 | 0.230 |
Why?
|
| Age Factors | 12 | 2018 | 5377 | 0.230 |
Why?
|
| Tracheostomy | 3 | 2021 | 243 | 0.230 |
Why?
|
| Incidence | 13 | 2015 | 5673 | 0.220 |
Why?
|
| Radiology | 1 | 2008 | 434 | 0.220 |
Why?
|
| Feasibility Studies | 7 | 2020 | 2292 | 0.220 |
Why?
|
| Patient Selection | 6 | 2020 | 2055 | 0.220 |
Why?
|
| Facial Bones | 1 | 2002 | 40 | 0.220 |
Why?
|
| Neoplasm Metastasis | 13 | 2018 | 5112 | 0.220 |
Why?
|
| Neoplasm Proteins | 4 | 2011 | 3230 | 0.210 |
Why?
|
| Alphapapillomavirus | 3 | 2014 | 171 | 0.210 |
Why?
|
| Prospective Studies | 23 | 2019 | 12873 | 0.210 |
Why?
|
| Patient Compliance | 3 | 2020 | 667 | 0.210 |
Why?
|
| Palliative Care | 3 | 2011 | 2037 | 0.210 |
Why?
|
| Vocal Cords | 2 | 2018 | 90 | 0.210 |
Why?
|
| Texas | 7 | 2020 | 6311 | 0.210 |
Why?
|
| Salivary Glands, Minor | 4 | 2012 | 33 | 0.210 |
Why?
|
| Anemia | 1 | 2007 | 689 | 0.210 |
Why?
|
| Drug Therapy, Combination | 4 | 1997 | 2315 | 0.200 |
Why?
|
| Sensitivity and Specificity | 10 | 2010 | 4971 | 0.200 |
Why?
|
| Speech | 3 | 2012 | 133 | 0.200 |
Why?
|
| Neoplasms | 3 | 2021 | 15193 | 0.200 |
Why?
|
| Radiation-Sensitizing Agents | 5 | 2015 | 363 | 0.200 |
Why?
|
| von Ebner Glands | 1 | 2020 | 3 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2014 | 7551 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myb | 2 | 2011 | 47 | 0.190 |
Why?
|
| Sarcoma, Synovial | 1 | 2002 | 119 | 0.190 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2020 | 27 | 0.190 |
Why?
|
| Pandemics | 2 | 2020 | 1559 | 0.190 |
Why?
|
| Carotid Arteries | 2 | 2019 | 240 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2015 | 7702 | 0.190 |
Why?
|
| Osteoradionecrosis | 1 | 2022 | 123 | 0.190 |
Why?
|
| Brachytherapy | 2 | 2007 | 977 | 0.190 |
Why?
|
| Oncology Service, Hospital | 1 | 2020 | 48 | 0.190 |
Why?
|
| Mucous Membrane | 2 | 2012 | 271 | 0.190 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 3719 | 0.180 |
Why?
|
| Organizational Innovation | 1 | 2020 | 68 | 0.180 |
Why?
|
| Glottis | 2 | 2019 | 67 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2015 | 8873 | 0.180 |
Why?
|
| Predictive Value of Tests | 11 | 2017 | 4892 | 0.180 |
Why?
|
| Radiation Injuries | 5 | 2012 | 1411 | 0.180 |
Why?
|
| Papilloma, Inverted | 1 | 2019 | 10 | 0.170 |
Why?
|
| Analysis of Variance | 7 | 2017 | 2307 | 0.170 |
Why?
|
| Acrospiroma | 1 | 2019 | 13 | 0.170 |
Why?
|
| Carcinoma, Acinar Cell | 3 | 2019 | 84 | 0.170 |
Why?
|
| Pilot Projects | 7 | 2021 | 2803 | 0.170 |
Why?
|
| Cranial Nerve Neoplasms | 2 | 1998 | 49 | 0.170 |
Why?
|
| Sulbactam | 3 | 1993 | 8 | 0.170 |
Why?
|
| Hypoglossal Nerve | 1 | 1998 | 6 | 0.170 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2020 | 117 | 0.170 |
Why?
|
| Ampicillin | 3 | 1993 | 58 | 0.170 |
Why?
|
| Signal Transduction | 4 | 2018 | 11965 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2015 | 716 | 0.170 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 1999 | 101 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2011 | 179 | 0.170 |
Why?
|
| Postoperative Care | 6 | 2017 | 739 | 0.170 |
Why?
|
| Radionuclide Imaging | 3 | 2014 | 660 | 0.160 |
Why?
|
| Hospitals, University | 2 | 2015 | 209 | 0.160 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2019 | 71 | 0.160 |
Why?
|
| Radiation Dosage | 6 | 2008 | 1014 | 0.160 |
Why?
|
| Dose-Response Relationship, Radiation | 6 | 2017 | 726 | 0.160 |
Why?
|
| Melanoma | 8 | 2018 | 5317 | 0.160 |
Why?
|
| Tumor Burden | 4 | 2018 | 1987 | 0.160 |
Why?
|
| Surveys and Questionnaires | 7 | 2021 | 5687 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 270 | 0.160 |
Why?
|
| Punctures | 2 | 2016 | 104 | 0.150 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 30 | 0.150 |
Why?
|
| Premedication | 3 | 1993 | 135 | 0.150 |
Why?
|
| DNA Methylation | 4 | 2011 | 2669 | 0.150 |
Why?
|
| Muscarinic Agonists | 2 | 2007 | 40 | 0.150 |
Why?
|
| Esophageal Neoplasms | 2 | 2006 | 3168 | 0.150 |
Why?
|
| Endoscopy | 3 | 2010 | 479 | 0.150 |
Why?
|
| DNA Repair | 3 | 2011 | 1872 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 761 | 0.150 |
Why?
|
| Waiting Lists | 1 | 2019 | 263 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2015 | 419 | 0.150 |
Why?
|
| Smoking | 8 | 2016 | 2440 | 0.150 |
Why?
|
| Palatal Neoplasms | 3 | 1995 | 26 | 0.150 |
Why?
|
| Adenolymphoma | 2 | 2008 | 27 | 0.140 |
Why?
|
| Reproducibility of Results | 8 | 2017 | 6009 | 0.140 |
Why?
|
| Barium | 1 | 2016 | 26 | 0.140 |
Why?
|
| Speech, Alaryngeal | 1 | 2016 | 24 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 289 | 0.140 |
Why?
|
| Proton Therapy | 3 | 2016 | 1577 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 651 | 0.140 |
Why?
|
| Papillomaviridae | 4 | 2019 | 624 | 0.140 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 1323 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 3 | 2018 | 2518 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1997 | 181 | 0.140 |
Why?
|
| Papilloma | 3 | 1994 | 74 | 0.140 |
Why?
|
| Emollients | 1 | 1995 | 12 | 0.140 |
Why?
|
| Disease Management | 2 | 2019 | 1052 | 0.140 |
Why?
|
| Polyurethanes | 1 | 1995 | 36 | 0.140 |
Why?
|
| Petrolatum | 1 | 1995 | 11 | 0.140 |
Why?
|
| Paclitaxel | 6 | 2009 | 1996 | 0.130 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1995 | 68 | 0.130 |
Why?
|
| Bandages | 1 | 1995 | 71 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 698 | 0.130 |
Why?
|
| Skull Base Neoplasms | 2 | 2015 | 314 | 0.130 |
Why?
|
| Myoepithelioma | 1 | 2015 | 31 | 0.130 |
Why?
|
| Receptors, Androgen | 3 | 2021 | 878 | 0.130 |
Why?
|
| Skin | 4 | 2005 | 1259 | 0.130 |
Why?
|
| Cetuximab | 4 | 2022 | 472 | 0.130 |
Why?
|
| Keratoacanthoma | 1 | 1994 | 18 | 0.130 |
Why?
|
| Carcinoma, Skin Appendage | 1 | 1994 | 12 | 0.130 |
Why?
|
| Anastomosis, Surgical | 2 | 2010 | 371 | 0.130 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1998 | 393 | 0.130 |
Why?
|
| Blood Component Transfusion | 1 | 2015 | 89 | 0.130 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 860 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2015 | 290 | 0.120 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 152 | 0.120 |
Why?
|
| Esophageal Stenosis | 2 | 2005 | 83 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2017 | 388 | 0.120 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2007 | 690 | 0.120 |
Why?
|
| Thyroglobulin | 1 | 2014 | 62 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2017 | 3639 | 0.120 |
Why?
|
| Re-Irradiation | 1 | 2016 | 163 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 1999 | 500 | 0.120 |
Why?
|
| Research Support as Topic | 3 | 2009 | 122 | 0.120 |
Why?
|
| Mandibular Neoplasms | 2 | 2009 | 76 | 0.120 |
Why?
|
| Ipilimumab | 1 | 2018 | 710 | 0.120 |
Why?
|
| Speech Intelligibility | 4 | 2016 | 40 | 0.120 |
Why?
|
| Tonsillectomy | 1 | 2014 | 102 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2011 | 479 | 0.110 |
Why?
|
| Program Development | 1 | 2015 | 261 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 5 | 2011 | 3101 | 0.110 |
Why?
|
| Blotting, Western | 5 | 2011 | 3536 | 0.110 |
Why?
|
| Thigh | 2 | 2010 | 172 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 986 | 0.110 |
Why?
|
| Fluorouracil | 7 | 2012 | 1944 | 0.110 |
Why?
|
| Registries | 5 | 2011 | 2170 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2018 | 1678 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 2 | 2013 | 545 | 0.110 |
Why?
|
| Risk | 3 | 2007 | 1972 | 0.110 |
Why?
|
| Laryngeal Diseases | 2 | 2008 | 49 | 0.110 |
Why?
|
| Nutrition Policy | 1 | 2013 | 111 | 0.110 |
Why?
|
| Induction Chemotherapy | 2 | 2015 | 669 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2017 | 674 | 0.110 |
Why?
|
| Physicians | 1 | 2021 | 882 | 0.110 |
Why?
|
| Mutation | 8 | 2020 | 15179 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 1 | 2015 | 408 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 1997 | 2992 | 0.110 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 1048 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2016 | 2291 | 0.110 |
Why?
|
| Comorbidity | 5 | 2018 | 2352 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 524 | 0.110 |
Why?
|
| Retinal Dehydrogenase | 1 | 2012 | 91 | 0.100 |
Why?
|
| Forecasting | 2 | 2013 | 694 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2013 | 650 | 0.100 |
Why?
|
| Esophagoscopy | 2 | 2005 | 291 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 1022 | 0.100 |
Why?
|
| Adenoma, Pleomorphic | 4 | 2005 | 63 | 0.100 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1992 | 73 | 0.100 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 4314 | 0.100 |
Why?
|
| Sinusitis | 2 | 1996 | 131 | 0.100 |
Why?
|
| Mastoid | 1 | 2011 | 26 | 0.100 |
Why?
|
| Hypothyroidism | 2 | 2009 | 204 | 0.100 |
Why?
|
| Base Sequence | 5 | 2014 | 4917 | 0.100 |
Why?
|
| Esophagus | 3 | 2016 | 553 | 0.100 |
Why?
|
| Membrane Glycoproteins | 2 | 2007 | 1073 | 0.100 |
Why?
|
| Protein Array Analysis | 2 | 2011 | 501 | 0.100 |
Why?
|
| Prevalence | 4 | 2016 | 3260 | 0.100 |
Why?
|
| Glossectomy | 1 | 1991 | 40 | 0.100 |
Why?
|
| Trachea | 2 | 2016 | 259 | 0.100 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 622 | 0.100 |
Why?
|
| Anthracenes | 1 | 2011 | 48 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2011 | 347 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2001 | 852 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2019 | 1143 | 0.100 |
Why?
|
| Ultraviolet Rays | 4 | 2007 | 575 | 0.100 |
Why?
|
| Epithelium | 2 | 2008 | 720 | 0.100 |
Why?
|
| Salivation | 2 | 2007 | 20 | 0.090 |
Why?
|
| CpG Islands | 2 | 2011 | 633 | 0.090 |
Why?
|
| Severity of Illness Index | 5 | 2009 | 4320 | 0.090 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2011 | 99 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2021 | 3341 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 1070 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2013 | 2450 | 0.090 |
Why?
|
| Oncogene Fusion | 1 | 2010 | 63 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 383 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2013 | 4549 | 0.090 |
Why?
|
| Remission Induction | 9 | 2012 | 3569 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 343 | 0.090 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 2 | 2004 | 19 | 0.090 |
Why?
|
| Pharyngectomy | 1 | 2010 | 44 | 0.090 |
Why?
|
| Genome-Wide Association Study | 2 | 2016 | 2265 | 0.090 |
Why?
|
| Social Desirability | 1 | 2010 | 22 | 0.090 |
Why?
|
| Immunoglobulin A | 2 | 1988 | 237 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2016 | 2588 | 0.090 |
Why?
|
| Social Identification | 1 | 2010 | 22 | 0.090 |
Why?
|
| Authorship | 5 | 2008 | 53 | 0.090 |
Why?
|
| Age Distribution | 4 | 2013 | 698 | 0.090 |
Why?
|
| Hypoparathyroidism | 2 | 2004 | 49 | 0.090 |
Why?
|
| Case-Control Studies | 8 | 2019 | 6100 | 0.090 |
Why?
|
| Isoenzymes | 1 | 2012 | 614 | 0.090 |
Why?
|
| Ethics, Research | 2 | 2007 | 67 | 0.090 |
Why?
|
| Social Isolation | 1 | 2010 | 64 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 4 | 2011 | 3203 | 0.090 |
Why?
|
| Electrosurgery | 1 | 1989 | 28 | 0.090 |
Why?
|
| Eyelid Neoplasms | 1 | 2011 | 191 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2011 | 1823 | 0.090 |
Why?
|
| Pharyngeal Diseases | 3 | 2016 | 53 | 0.090 |
Why?
|
| Hemostasis, Surgical | 1 | 1989 | 48 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2015 | 2488 | 0.090 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 14551 | 0.090 |
Why?
|
| Exome | 3 | 2023 | 1239 | 0.090 |
Why?
|
| Bacteria | 1 | 1993 | 611 | 0.090 |
Why?
|
| Lip Neoplasms | 1 | 1989 | 18 | 0.090 |
Why?
|
| DNA Adducts | 1 | 2010 | 210 | 0.080 |
Why?
|
| Cell Count | 2 | 2000 | 508 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1274 | 0.080 |
Why?
|
| Sex Distribution | 3 | 2013 | 495 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2011 | 396 | 0.080 |
Why?
|
| Biopsy, Needle | 5 | 2013 | 1363 | 0.080 |
Why?
|
| Uvula | 1 | 1988 | 2 | 0.080 |
Why?
|
| Palatal Muscles | 1 | 1988 | 2 | 0.080 |
Why?
|
| Dissection | 1 | 1989 | 156 | 0.080 |
Why?
|
| MicroRNAs | 2 | 2013 | 2947 | 0.080 |
Why?
|
| Radiation Oncology | 2 | 2006 | 529 | 0.080 |
Why?
|
| Disease Progression | 6 | 2014 | 6682 | 0.080 |
Why?
|
| Carcinoma, Basosquamous | 1 | 2008 | 12 | 0.080 |
Why?
|
| Palate, Soft | 1 | 1988 | 28 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 1993 | 437 | 0.080 |
Why?
|
| ROC Curve | 3 | 2010 | 1183 | 0.080 |
Why?
|
| Urinary Tract Infections | 1 | 1993 | 321 | 0.080 |
Why?
|
| DNA Helicases | 1 | 2011 | 434 | 0.080 |
Why?
|
| Suture Techniques | 1 | 2010 | 319 | 0.080 |
Why?
|
| Stomatognathic System | 1 | 2007 | 1 | 0.080 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2011 | 259 | 0.080 |
Why?
|
| Morbidity | 2 | 2020 | 397 | 0.080 |
Why?
|
| Estrogen Receptor beta | 2 | 2007 | 155 | 0.080 |
Why?
|
| Maxillary Artery | 1 | 2007 | 4 | 0.080 |
Why?
|
| Cadherins | 2 | 2008 | 660 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.080 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2010 | 192 | 0.080 |
Why?
|
| Adipose Tissue | 3 | 2005 | 769 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 2 | 2000 | 345 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 5 | 2018 | 5395 | 0.080 |
Why?
|
| RNA, Neoplasm | 4 | 2019 | 771 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2005 | 1064 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 1265 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2007 | 712 | 0.080 |
Why?
|
| Skull Neoplasms | 1 | 2007 | 67 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2013 | 2508 | 0.080 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2007 | 39 | 0.080 |
Why?
|
| Patients | 1 | 2010 | 245 | 0.080 |
Why?
|
| Ethics | 1 | 2007 | 30 | 0.070 |
Why?
|
| Frontal Bone | 1 | 1987 | 22 | 0.070 |
Why?
|
| Muscles | 1 | 1988 | 416 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 748 | 0.070 |
Why?
|
| Journalism, Medical | 1 | 2007 | 11 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2008 | 327 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 1988 | 423 | 0.070 |
Why?
|
| Mutagens | 2 | 2006 | 187 | 0.070 |
Why?
|
| Microsatellite Repeats | 3 | 2017 | 575 | 0.070 |
Why?
|
| Bacteremia | 1 | 1993 | 689 | 0.070 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2006 | 41 | 0.070 |
Why?
|
| Publications | 1 | 2007 | 54 | 0.070 |
Why?
|
| Surgery, Plastic | 2 | 1996 | 344 | 0.070 |
Why?
|
| Forearm | 1 | 2006 | 67 | 0.070 |
Why?
|
| Cranial Irradiation | 1 | 2008 | 315 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 5 | 2011 | 1165 | 0.070 |
Why?
|
| Elective Surgical Procedures | 2 | 2005 | 250 | 0.070 |
Why?
|
| Recurrence | 5 | 2020 | 4758 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 272 | 0.070 |
Why?
|
| Amphotericin B | 1 | 1987 | 289 | 0.070 |
Why?
|
| Isotretinoin | 5 | 1994 | 158 | 0.070 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 292 | 0.070 |
Why?
|
| Bone Transplantation | 1 | 1987 | 134 | 0.070 |
Why?
|
| Mesoderm | 1 | 2008 | 404 | 0.070 |
Why?
|
| Aneurysm, False | 1 | 2007 | 153 | 0.070 |
Why?
|
| Vagus Nerve Injuries | 1 | 1985 | 2 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 2139 | 0.070 |
Why?
|
| Chromatids | 1 | 2005 | 78 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 1987 | 223 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2000 | 2063 | 0.070 |
Why?
|
| Liposomes | 1 | 1987 | 684 | 0.070 |
Why?
|
| Aspergillosis | 1 | 1987 | 246 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2008 | 478 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2008 | 875 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2006 | 313 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 945 | 0.060 |
Why?
|
| Stomatitis | 3 | 2014 | 183 | 0.060 |
Why?
|
| Polytetrafluoroethylene | 1 | 1985 | 113 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2013 | 2819 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2005 | 96 | 0.060 |
Why?
|
| Leukoplakia, Oral | 3 | 1996 | 70 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2016 | 344 | 0.060 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 383 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2011 | 4804 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 915 | 0.060 |
Why?
|
| Radiography | 3 | 2006 | 1904 | 0.060 |
Why?
|
| Research Design | 3 | 2013 | 1544 | 0.060 |
Why?
|
| SEER Program | 4 | 2009 | 1000 | 0.060 |
Why?
|
| Vocal Cord Paralysis | 1 | 1985 | 82 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 1945 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2007 | 498 | 0.060 |
Why?
|
| Discriminant Analysis | 1 | 2003 | 48 | 0.060 |
Why?
|
| History, 18th Century | 1 | 2004 | 89 | 0.060 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2003 | 37 | 0.060 |
Why?
|
| Nasal Polyps | 1 | 2003 | 27 | 0.060 |
Why?
|
| Karyotyping | 2 | 2017 | 1022 | 0.060 |
Why?
|
| RNA, Messenger | 6 | 2011 | 6150 | 0.060 |
Why?
|
| Research | 1 | 2006 | 415 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 1547 | 0.060 |
Why?
|
| History, 21st Century | 2 | 2018 | 441 | 0.060 |
Why?
|
| Lymphatic System | 2 | 2010 | 64 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 1996 | 1914 | 0.060 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 799 | 0.060 |
Why?
|
| Heterografts | 2 | 2017 | 733 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 1248 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1990 | 882 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 216 | 0.060 |
Why?
|
| Health Resources | 2 | 2002 | 168 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2003 | 980 | 0.060 |
Why?
|
| DNA Repair Enzymes | 3 | 2011 | 237 | 0.060 |
Why?
|
| Animals | 9 | 2017 | 59536 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 1984 | 144 | 0.060 |
Why?
|
| Fibroblasts | 2 | 2000 | 1682 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2014 | 2370 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2003 | 295 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 2 | 2006 | 310 | 0.060 |
Why?
|
| Scientific Misconduct | 3 | 2007 | 21 | 0.060 |
Why?
|
| Growth Substances | 1 | 2003 | 300 | 0.060 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 610 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2004 | 602 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2005 | 362 | 0.050 |
Why?
|
| Sarcoma | 1 | 2013 | 1725 | 0.050 |
Why?
|
| Equipment Design | 1 | 2006 | 1204 | 0.050 |
Why?
|
| Riots | 1 | 2022 | 6 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2016 | 211 | 0.050 |
Why?
|
| Pennsylvania | 2 | 1999 | 64 | 0.050 |
Why?
|
| Philadelphia | 1 | 2002 | 38 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 2 | 1997 | 994 | 0.050 |
Why?
|
| Choristoma | 1 | 2002 | 85 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2003 | 205 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2003 | 233 | 0.050 |
Why?
|
| Surgery Department, Hospital | 1 | 2002 | 30 | 0.050 |
Why?
|
| Child, Preschool | 6 | 2013 | 16273 | 0.050 |
Why?
|
| Nasal Cavity | 3 | 2015 | 149 | 0.050 |
Why?
|
| Down-Regulation | 4 | 2010 | 2074 | 0.050 |
Why?
|
| Hematoma | 2 | 2016 | 160 | 0.050 |
Why?
|
| Cytokines | 1 | 2011 | 2809 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2009 | 806 | 0.050 |
Why?
|
| Safety | 1 | 2004 | 465 | 0.050 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2001 | 20 | 0.050 |
Why?
|
| Electrodes | 1 | 2002 | 116 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2004 | 829 | 0.050 |
Why?
|
| Esophagostomy | 1 | 2001 | 3 | 0.050 |
Why?
|
| Mandibular Osteotomy | 1 | 2022 | 33 | 0.050 |
Why?
|
| Vagus Nerve | 1 | 2002 | 63 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2010 | 2086 | 0.050 |
Why?
|
| Zenker Diverticulum | 1 | 2001 | 10 | 0.050 |
Why?
|
| Hospital Charges | 1 | 2002 | 75 | 0.050 |
Why?
|
| Early Detection of Cancer | 3 | 2019 | 1258 | 0.050 |
Why?
|
| Surgical Stapling | 1 | 2001 | 36 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 1984 | 268 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 2 | 2008 | 1350 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2003 | 477 | 0.050 |
Why?
|
| Laminin | 1 | 2001 | 194 | 0.050 |
Why?
|
| Voice Quality | 2 | 2015 | 33 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 1984 | 402 | 0.050 |
Why?
|
| Peripheral Nerves | 1 | 2001 | 159 | 0.050 |
Why?
|
| Sutures | 1 | 2001 | 86 | 0.050 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 30 | 0.050 |
Why?
|
| Rats | 2 | 2000 | 6086 | 0.050 |
Why?
|
| Saliva | 2 | 2006 | 231 | 0.050 |
Why?
|
| Gene Fusion | 2 | 2013 | 209 | 0.050 |
Why?
|
| Pneumonia | 2 | 2020 | 751 | 0.050 |
Why?
|
| Probability | 3 | 2009 | 866 | 0.050 |
Why?
|
| Genes, p53 | 2 | 1995 | 1090 | 0.050 |
Why?
|
| Thyroid Nodule | 1 | 2001 | 92 | 0.050 |
Why?
|
| Mucositis | 2 | 2014 | 148 | 0.050 |
Why?
|
| Etanidazole | 1 | 2000 | 12 | 0.050 |
Why?
|
| Seminoma | 1 | 2000 | 81 | 0.050 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2000 | 26 | 0.050 |
Why?
|
| Serrate-Jagged Proteins | 2 | 2013 | 85 | 0.050 |
Why?
|
| Clinical Protocols | 2 | 2020 | 467 | 0.050 |
Why?
|
| Random Allocation | 2 | 2000 | 703 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2020 | 83 | 0.050 |
Why?
|
| Jagged-1 Protein | 2 | 2013 | 101 | 0.050 |
Why?
|
| Enteral Nutrition | 2 | 2013 | 316 | 0.040 |
Why?
|
| Fistula | 1 | 2020 | 76 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 95 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2020 | 81 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 1742 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 205 | 0.040 |
Why?
|
| Organs at Risk | 2 | 2012 | 514 | 0.040 |
Why?
|
| DNA Damage | 1 | 2007 | 1954 | 0.040 |
Why?
|
| Drainage | 1 | 2022 | 416 | 0.040 |
Why?
|
| Device Removal | 1 | 2021 | 337 | 0.040 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2019 | 36 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2014 | 829 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2000 | 360 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2000 | 328 | 0.040 |
Why?
|
| Ganglia, Sympathetic | 1 | 1998 | 32 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2019 | 96 | 0.040 |
Why?
|
| DNA, Viral | 2 | 1994 | 694 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2006 | 1000 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 502 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 98 | 0.040 |
Why?
|
| Diagnostic Techniques, Surgical | 1 | 1998 | 4 | 0.040 |
Why?
|
| Genes, Homeobox | 1 | 2019 | 147 | 0.040 |
Why?
|
| Extremities | 1 | 2000 | 303 | 0.040 |
Why?
|
| Taxoids | 2 | 2015 | 967 | 0.040 |
Why?
|
| Nutrition Disorders | 1 | 1998 | 57 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2010 | 234 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 175 | 0.040 |
Why?
|
| Neck Muscles | 1 | 1998 | 38 | 0.040 |
Why?
|
| Fasciotomy | 1 | 1998 | 43 | 0.040 |
Why?
|
| Demography | 2 | 2012 | 435 | 0.040 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1998 | 79 | 0.040 |
Why?
|
| Wound Healing | 2 | 2011 | 815 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 2594 | 0.040 |
Why?
|
| DNA Primers | 2 | 2014 | 1399 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2005 | 1058 | 0.040 |
Why?
|
| Fascia | 1 | 1998 | 68 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2000 | 176 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 4367 | 0.040 |
Why?
|
| Fibromatosis, Aggressive | 1 | 1998 | 109 | 0.040 |
Why?
|
| Gadolinium DTPA | 1 | 1998 | 172 | 0.040 |
Why?
|
| Adenoma | 1 | 2002 | 716 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2001 | 384 | 0.040 |
Why?
|
| Diagnosis, Differential | 5 | 2007 | 4744 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2003 | 1529 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1491 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2002 | 445 | 0.040 |
Why?
|
| Time | 1 | 2017 | 178 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 750 | 0.040 |
Why?
|
| Biopsy | 3 | 2017 | 3443 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2016 | 2316 | 0.040 |
Why?
|
| Lip Diseases | 1 | 1996 | 4 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2016 | 46 | 0.040 |
Why?
|
| DNA Modification Methylases | 2 | 2008 | 172 | 0.040 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2019 | 222 | 0.040 |
Why?
|
| DNA Copy Number Variations | 2 | 2014 | 1516 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2021 | 773 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 577 | 0.040 |
Why?
|
| Lip | 1 | 1996 | 33 | 0.040 |
Why?
|
| Cutaneous Fistula | 1 | 2016 | 46 | 0.040 |
Why?
|
| Decision Making | 1 | 2004 | 1287 | 0.040 |
Why?
|
| Testicular Neoplasms | 1 | 2000 | 529 | 0.040 |
Why?
|
| Maxillofacial Prosthesis | 1 | 1996 | 15 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 521 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 3472 | 0.040 |
Why?
|
| Gene Expression | 3 | 2014 | 3570 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2020 | 451 | 0.030 |
Why?
|
| Pterygoid Muscles | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 77 | 0.030 |
Why?
|
| Co-Repressor Proteins | 2 | 2007 | 122 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2016 | 129 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2008 | 365 | 0.030 |
Why?
|
| Surgical Sponges | 1 | 1995 | 3 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2009 | 756 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2012 | 1546 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 978 | 0.030 |
Why?
|
| Craniotomy | 2 | 1996 | 304 | 0.030 |
Why?
|
| Protein Isoforms | 2 | 2011 | 842 | 0.030 |
Why?
|
| Genes, Neoplasm | 2 | 2008 | 324 | 0.030 |
Why?
|
| Cricoid Cartilage | 1 | 2015 | 19 | 0.030 |
Why?
|
| Hong Kong | 1 | 2015 | 71 | 0.030 |
Why?
|
| Absorption | 1 | 1995 | 81 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 295 | 0.030 |
Why?
|
| Neutron Capture Therapy | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2019 | 2359 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2011 | 1618 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2015 | 104 | 0.030 |
Why?
|
| Gene Order | 1 | 2015 | 111 | 0.030 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 1162 | 0.030 |
Why?
|
| Plagiarism | 2 | 2005 | 9 | 0.030 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2017 | 202 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2017 | 285 | 0.030 |
Why?
|
| Brazil | 1 | 2015 | 165 | 0.030 |
Why?
|
| Models, Biological | 1 | 2004 | 3254 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 1163 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1988 | 2326 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 568 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2001 | 808 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 418 | 0.030 |
Why?
|
| Heavy Ion Radiotherapy | 1 | 2015 | 25 | 0.030 |
Why?
|
| Contrast Media | 2 | 2001 | 1472 | 0.030 |
Why?
|
| Permeability | 1 | 1995 | 167 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2016 | 299 | 0.030 |
Why?
|
| Proteins | 1 | 2003 | 1963 | 0.030 |
Why?
|
| Carcinogens | 3 | 2010 | 384 | 0.030 |
Why?
|
| Human Experimentation | 2 | 2005 | 51 | 0.030 |
Why?
|
| Vocal Cord Dysfunction | 1 | 2015 | 15 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2014 | 4307 | 0.030 |
Why?
|
| Postoperative Period | 2 | 2014 | 665 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 15694 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Culture Media, Serum-Free | 1 | 2014 | 74 | 0.030 |
Why?
|
| Carbon | 1 | 2015 | 149 | 0.030 |
Why?
|
| Pain Management | 1 | 2020 | 668 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 702 | 0.030 |
Why?
|
| Mice | 5 | 2017 | 34495 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2015 | 317 | 0.030 |
Why?
|
| Confidentiality | 2 | 2005 | 127 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 649 | 0.030 |
Why?
|
| Drug Evaluation | 3 | 1992 | 425 | 0.030 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1994 | 37 | 0.030 |
Why?
|
| Image Enhancement | 1 | 1998 | 561 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2015 | 430 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1995 | 306 | 0.030 |
Why?
|
| Phenotype | 3 | 2015 | 6295 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2013 | 2218 | 0.030 |
Why?
|
| China | 1 | 2015 | 606 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1489 | 0.030 |
Why?
|
| Genomics | 2 | 2015 | 2738 | 0.030 |
Why?
|
| Nose | 1 | 1996 | 192 | 0.030 |
Why?
|
| Cell Division | 3 | 2002 | 2489 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1988 | 3022 | 0.030 |
Why?
|
| Hypersensitivity | 1 | 1996 | 216 | 0.030 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2014 | 80 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2000 | 2843 | 0.030 |
Why?
|
| Chromones | 2 | 2005 | 120 | 0.030 |
Why?
|
| Genes, myb | 1 | 2013 | 13 | 0.030 |
Why?
|
| Laryngeal Nerve Injuries | 1 | 1993 | 2 | 0.030 |
Why?
|
| Ploidies | 2 | 2010 | 248 | 0.030 |
Why?
|
| Water | 1 | 1995 | 361 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 598 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2018 | 1442 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2013 | 170 | 0.030 |
Why?
|
| Hyperthyroidism | 1 | 1993 | 52 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1994 | 224 | 0.030 |
Why?
|
| Secretory Rate | 2 | 2006 | 16 | 0.030 |
Why?
|
| Hyperparathyroidism | 1 | 1993 | 93 | 0.030 |
Why?
|
| Cell Differentiation | 4 | 2015 | 4078 | 0.030 |
Why?
|
| Mycoses | 1 | 1996 | 386 | 0.030 |
Why?
|
| Tracheal Neoplasms | 1 | 1993 | 42 | 0.030 |
Why?
|
| Binding Sites | 2 | 2011 | 2171 | 0.030 |
Why?
|
| Wound Infection | 1 | 1993 | 54 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 1506 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 734 | 0.030 |
Why?
|
| Uncertainty | 1 | 2014 | 320 | 0.030 |
Why?
|
| Carotenoids | 1 | 1993 | 96 | 0.030 |
Why?
|
| Morpholines | 2 | 2005 | 289 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 1 | 2015 | 334 | 0.030 |
Why?
|
| Informed Consent | 2 | 2005 | 419 | 0.030 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1993 | 137 | 0.030 |
Why?
|
| Genes, Developmental | 1 | 2011 | 12 | 0.030 |
Why?
|
| Psychometrics | 1 | 2016 | 937 | 0.030 |
Why?
|
| Cineradiography | 1 | 1991 | 4 | 0.030 |
Why?
|
| Brain Stem | 1 | 2012 | 175 | 0.030 |
Why?
|
| Radiography, Interventional | 2 | 2007 | 305 | 0.030 |
Why?
|
| Pain Measurement | 1 | 1995 | 953 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 3251 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2019 | 1664 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 1995 | 341 | 0.020 |
Why?
|
| Ear, Middle | 1 | 1991 | 48 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2014 | 584 | 0.020 |
Why?
|
| Palatal Obturators | 1 | 1991 | 17 | 0.020 |
Why?
|
| Competitive Bidding | 1 | 2010 | 1 | 0.020 |
Why?
|
| Ku Autoantigen | 1 | 2011 | 79 | 0.020 |
Why?
|
| Telomerase | 1 | 2014 | 525 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 447 | 0.020 |
Why?
|
| Eating | 1 | 2013 | 421 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1993 | 621 | 0.020 |
Why?
|
| Ear Neoplasms | 1 | 1991 | 59 | 0.020 |
Why?
|
| Speech Disorders | 1 | 1991 | 91 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 1371 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2012 | 298 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 691 | 0.020 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 2216 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2011 | 331 | 0.020 |
Why?
|
| Luciferases | 1 | 2011 | 445 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 611 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 760 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 1991 | 232 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2013 | 351 | 0.020 |
Why?
|
| Oral Fistula | 1 | 2009 | 8 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1819 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 665 | 0.020 |
Why?
|
| Oncogenes | 1 | 2013 | 673 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1997 | 1960 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 1471 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 323 | 0.020 |
Why?
|
| ras Proteins | 2 | 2005 | 770 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 483 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2004 | 11538 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 1833 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 1993 | 649 | 0.020 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2010 | 209 | 0.020 |
Why?
|
| Cefazolin | 1 | 1988 | 25 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2011 | 316 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 690 | 0.020 |
Why?
|
| Hypergammaglobulinemia | 1 | 1988 | 19 | 0.020 |
Why?
|
| Human papillomavirus 16 | 1 | 2010 | 256 | 0.020 |
Why?
|
| Zygoma | 1 | 2007 | 12 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 1989 | 216 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2010 | 414 | 0.020 |
Why?
|
| Spectral Karyotyping | 1 | 2007 | 13 | 0.020 |
Why?
|
| Taste Disorders | 1 | 2007 | 17 | 0.020 |
Why?
|
| Mastication | 1 | 2007 | 19 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Rupture | 1 | 2007 | 61 | 0.020 |
Why?
|
| Sweat | 1 | 2007 | 10 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2007 | 15 | 0.020 |
Why?
|
| Contraindications | 1 | 2008 | 150 | 0.020 |
Why?
|
| Methods | 1 | 1987 | 189 | 0.020 |
Why?
|
| Metronidazole | 1 | 1988 | 149 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1217 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2013 | 598 | 0.020 |
Why?
|
| Nasal Septum | 1 | 2007 | 47 | 0.020 |
Why?
|
| Voice Disorders | 1 | 2007 | 39 | 0.020 |
Why?
|
| Diagnostic Errors | 2 | 2002 | 509 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 1988 | 89 | 0.020 |
Why?
|
| Health Transition | 1 | 2007 | 9 | 0.020 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2006 | 22 | 0.020 |
Why?
|
| Genome, Human | 1 | 2015 | 1869 | 0.020 |
Why?
|
| Retreatment | 1 | 2008 | 452 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2010 | 731 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2010 | 641 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 542 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 1084 | 0.020 |
Why?
|
| Survivors | 1 | 2012 | 1031 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2013 | 1026 | 0.020 |
Why?
|
| Dyspepsia | 1 | 2007 | 103 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2007 | 160 | 0.020 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2006 | 97 | 0.020 |
Why?
|
| Peer Review, Health Care | 1 | 2006 | 30 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2006 | 61 | 0.020 |
Why?
|
| Technology, Radiologic | 1 | 2006 | 80 | 0.020 |
Why?
|
| Staff Development | 1 | 2006 | 61 | 0.020 |
Why?
|
| Laryngoscopes | 1 | 2008 | 86 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2006 | 133 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2009 | 349 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2003 | 1391 | 0.020 |
Why?
|
| Peer Review, Research | 1 | 2007 | 66 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2011 | 621 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1988 | 419 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 206 | 0.020 |
Why?
|
| Sunburn | 1 | 2005 | 35 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 1879 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 208 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2006 | 226 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 7573 | 0.020 |
Why?
|
| Swine | 1 | 2010 | 1541 | 0.020 |
Why?
|
| Personnel Selection | 1 | 2006 | 87 | 0.020 |
Why?
|
| Nausea | 1 | 2007 | 525 | 0.020 |
Why?
|
| Radiation Tolerance | 2 | 2002 | 629 | 0.020 |
Why?
|
| Complement C4 | 1 | 1984 | 15 | 0.020 |
Why?
|
| Sulfasalazine | 1 | 1984 | 16 | 0.020 |
Why?
|
| Anesthesia, Local | 1 | 1985 | 66 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 1493 | 0.020 |
Why?
|
| Flow Cytometry | 4 | 1993 | 3033 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 1085 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 299 | 0.020 |
Why?
|
| Social Class | 1 | 2006 | 310 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2005 | 178 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2005 | 206 | 0.020 |
Why?
|
| Injections | 1 | 1985 | 285 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 1303 | 0.020 |
Why?
|
| Interferon-alpha | 3 | 1994 | 889 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 1764 | 0.020 |
Why?
|
| Career Choice | 1 | 2006 | 232 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 5539 | 0.020 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2003 | 7 | 0.020 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2003 | 18 | 0.020 |
Why?
|
| Minority Groups | 1 | 2006 | 322 | 0.010 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2003 | 27 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2003 | 132 | 0.010 |
Why?
|
| Nerve Growth Factor | 1 | 2003 | 45 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2006 | 621 | 0.010 |
Why?
|
| Dilatation | 1 | 2004 | 83 | 0.010 |
Why?
|
| Diarrhea | 1 | 2007 | 686 | 0.010 |
Why?
|
| Medicare | 1 | 2008 | 860 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 2004 | 137 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 2006 | 289 | 0.010 |
Why?
|
| Cell Movement | 1 | 2011 | 2466 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1990 | 962 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 2003 | 85 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2003 | 226 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 2483 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 538 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2005 | 269 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1988 | 904 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2007 | 551 | 0.010 |
Why?
|
| Health Status | 1 | 2006 | 590 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1984 | 675 | 0.010 |
Why?
|
| Observer Variation | 1 | 2004 | 671 | 0.010 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2003 | 268 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 335 | 0.010 |
Why?
|
| Diploidy | 2 | 1993 | 114 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 577 | 0.010 |
Why?
|
| Laryngismus | 1 | 2001 | 6 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 2001 | 40 | 0.010 |
Why?
|
| Global Health | 1 | 2007 | 657 | 0.010 |
Why?
|
| Pneumonia, Aspiration | 1 | 2001 | 41 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 7222 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1999 | 5319 | 0.010 |
Why?
|
| Electromyography | 1 | 2002 | 226 | 0.010 |
Why?
|
| Fatigue | 1 | 2007 | 1239 | 0.010 |
Why?
|
| Radiotherapy, Conformal | 1 | 2006 | 902 | 0.010 |
Why?
|
| Curriculum | 1 | 2006 | 860 | 0.010 |
Why?
|
| Cell Line | 1 | 1988 | 5114 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1984 | 1021 | 0.010 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2000 | 110 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 1054 | 0.010 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2000 | 122 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2000 | 211 | 0.010 |
Why?
|
| Cough | 1 | 2001 | 116 | 0.010 |
Why?
|
| Hypertension | 1 | 2009 | 1503 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1984 | 1234 | 0.010 |
Why?
|
| Home Infusion Therapy | 1 | 1999 | 12 | 0.010 |
Why?
|
| Rabbits | 1 | 2000 | 957 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 3890 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 1658 | 0.010 |
Why?
|
| Transgenes | 1 | 2000 | 557 | 0.010 |
Why?
|
| Leukemia | 1 | 1987 | 1635 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 798 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 1439 | 0.010 |
Why?
|
| Epiglottis | 1 | 1997 | 12 | 0.010 |
Why?
|
| Dehydration | 1 | 1998 | 87 | 0.010 |
Why?
|
| Mass Screening | 1 | 2006 | 1509 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2003 | 1392 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 1130 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1998 | 220 | 0.010 |
Why?
|
| Skull Base | 1 | 1998 | 199 | 0.010 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2000 | 494 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1994 | 2927 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 1999 | 256 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 7591 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 2022 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 1382 | 0.010 |
Why?
|
| Paranasal Sinuses | 1 | 1996 | 61 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2001 | 899 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1995 | 159 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2008 | 3518 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 176 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 1998 | 429 | 0.010 |
Why?
|
| Dura Mater | 1 | 1995 | 73 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 2522 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1988 | 3869 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 7226 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 2195 | 0.010 |
Why?
|
| Neutropenia | 1 | 1999 | 968 | 0.010 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1995 | 64 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2002 | 2054 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 1991 | 5767 | 0.010 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 1995 | 77 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 1099 | 0.010 |
Why?
|
| Weight Loss | 1 | 1998 | 627 | 0.010 |
Why?
|
| Orbital Neoplasms | 1 | 1996 | 224 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2000 | 4143 | 0.010 |
Why?
|
| beta Carotene | 1 | 1993 | 76 | 0.010 |
Why?
|
| Bleomycin | 1 | 1994 | 467 | 0.010 |
Why?
|
| Point Mutation | 1 | 1995 | 769 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 3552 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2000 | 1429 | 0.010 |
Why?
|
| Nervous System Neoplasms | 1 | 1990 | 36 | 0.010 |
Why?
|
| Micronucleus Tests | 1 | 1990 | 20 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1990 | 185 | 0.010 |
Why?
|
| Transglutaminases | 1 | 1990 | 99 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1990 | 369 | 0.010 |
Why?
|
| Hospitalization | 1 | 1998 | 2083 | 0.010 |
Why?
|
| Bacteria, Anaerobic | 1 | 1988 | 8 | 0.010 |
Why?
|
| Keratins | 1 | 1990 | 330 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1990 | 240 | 0.010 |
Why?
|
| Cobalt Radioisotopes | 1 | 1988 | 42 | 0.000 |
Why?
|
| Orbit | 1 | 1989 | 205 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 6089 | 0.000 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1988 | 295 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1988 | 479 | 0.000 |
Why?
|
| Infant | 1 | 1998 | 13310 | 0.000 |
Why?
|